{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T21:14:18Z","timestamp":1776201258754,"version":"3.50.1"},"reference-count":29,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001738","name":"Israel Ministry of Innovation Science & Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100024250","name":"Israel Innovation Authority","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100024250","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003977","name":"Israel Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003977","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Methods & Clinical Development"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.omtm.2025.101632","type":"journal-article","created":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T01:38:24Z","timestamp":1763084304000},"page":"101632","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Leveraging the active conformation of LFA-1 as a potential target for hematological malignancies"],"prefix":"10.1016","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6310-3328","authenticated-orcid":false,"given":"Abhishek","family":"Puthenveetil","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guy","family":"Biber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Batel","family":"Sabag","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meirav","family":"Kedmi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Avigdor","family":"Abraham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noah","family":"Joseph","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0305-7438","authenticated-orcid":false,"given":"Mira","family":"Barda-Saad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtm.2025.101632_bib1","first-page":"7","article-title":"Cancer statistics","volume":"68","author":"Siegel","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.omtm.2025.101632_bib2","first-page":"1","article-title":"Monoclonal antibodies in cancer therapy | Cancer Immunity","volume":"12","author":"Scott","year":"2012","journal-title":"Cancer Immun."},{"key":"10.1016\/j.omtm.2025.101632_bib3","doi-asserted-by":"crossref","first-page":"4111","DOI":"10.1182\/blood-2014-03-560284","article-title":"Acquired mutations in BCL2 family proteins conferring resistance to the BH3 mimetic ABT-199 in lymphoma","volume":"123","author":"Fresquet","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.omtm.2025.101632_bib4","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1056\/NEJMoa012914","article-title":"The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma","volume":"346","author":"Rosenwald","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omtm.2025.101632_bib5","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/S0145-2126(99)00036-3","article-title":"Expression of LFA-1 identifies different prognostic subgroups in patients with advanced follicle center lymphoma (FCL)","volume":"23","author":"Bechter","year":"1999","journal-title":"Leuk. Res."},{"key":"10.1016\/j.omtm.2025.101632_bib6","first-page":"848","article-title":"Expression of the leucocyte integrin LFA-1 (CD11a\/CD18) and its ligand ICAM-1 (CD54) in lymphoid malignancies is related to lineage derivation and stage of differentiation but not to tumor grade","volume":"5","author":"Horst","year":"1991","journal-title":"Leukemia"},{"key":"10.1016\/j.omtm.2025.101632_bib7","doi-asserted-by":"crossref","first-page":"153","DOI":"10.3390\/cancers9110153","article-title":"Role of LFA-1 and ICAM-1 in cancer","volume":"9","author":"Reina","year":"2017","journal-title":"Cancers"},{"key":"10.1016\/j.omtm.2025.101632_bib8","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/nrd1632","article-title":"Recent advances with liposomes as pharmaceutical carriers","volume":"4","author":"Torchilin","year":"2005","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.omtm.2025.101632_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2013\/705265","article-title":"Recent trends in multifunctional liposomal nanocarriers for enhanced tumor targeting","volume":"2013","author":"Perche","year":"2013","journal-title":"J Drug Deliv"},{"key":"10.1016\/j.omtm.2025.101632_bib10","doi-asserted-by":"crossref","first-page":"5629","DOI":"10.4049\/jimmunol.166.9.5629","article-title":"Epitope Mapping of Antibodies to the C-Terminal Region of the Integrin 2 Subunit Reveals Regions that Become Exposed Upon Receptor Activation","volume":"166","author":"Lu","year":"2001","journal-title":"J. Immunol."},{"key":"10.1016\/j.omtm.2025.101632_bib11","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1091\/mbc.8.4.719","article-title":"Cytoplasmic tails of beta 1, beta 2, and beta 7 integrins differentially regulate LFA-1 function in K562 cells","volume":"8","author":"Lub","year":"1997","journal-title":"MBoC."},{"key":"10.1016\/j.omtm.2025.101632_bib12","doi-asserted-by":"crossref","first-page":"5581","DOI":"10.1038\/s41467-021-25842-7","article-title":"Targeting the actin nucleation promoting factor WASp provides a therapeutic approach for hematopoietic malignancies","volume":"12","author":"Biber","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtm.2025.101632_bib13","doi-asserted-by":"crossref","first-page":"279","DOI":"10.3324\/haematol.2011.052829","article-title":"CD69 is independently prognostic in chronic lymphocytic leukemia: A comprehensive clinical and biological profiling study","volume":"97","author":"Del","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.omtm.2025.101632_bib14","doi-asserted-by":"crossref","first-page":"5507","DOI":"10.18632\/oncotarget.6685","article-title":"CD69 expression potentially predicts response to bendamustine and its modulation by ibrutinib or idelalisib enhances cytotoxic effect in chronic lymphocytic leukemia","volume":"7","author":"Montraveta","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.omtm.2025.101632_bib15","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3390\/cancers14010087","article-title":"FDA-Approved Drugs for Hematological Malignancies\u2014The Last Decade Review","volume":"14","author":"Sochacka-\u0107wik\u0142a","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.omtm.2025.101632_bib16","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-023-01460-2","article-title":"Development and application of nanomaterials, nanotechnology and nanomedicine for treating hematological malignancies","volume":"16","author":"Li","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.omtm.2025.101632_bib17","doi-asserted-by":"crossref","first-page":"553","DOI":"10.5306\/wjco.v13.i7.553","article-title":"Nanomedicine approaches for treatment of hematologic and oncologic malignancies","volume":"13","author":"Nteli","year":"2022","journal-title":"World J. Clin. Oncol."},{"key":"10.1016\/j.omtm.2025.101632_bib18","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.leukres.2015.03.010","article-title":"LFA-1-targeting Leukotoxin (LtxA; Leukothera\u00ae) causes lymphoma tumor regression in a humanized mouse model and requires caspase-8 and Fas to kill malignant lymphocytes","volume":"39","author":"DiFranco","year":"2015","journal-title":"Leuk. Res."},{"key":"10.1016\/j.omtm.2025.101632_bib19","doi-asserted-by":"crossref","first-page":"17618","DOI":"10.1074\/jbc.M111.314674","article-title":"Leukotoxin (Leukothera\u00ae) targets active leukocyte function antigen-1 (LFA-1) protein and triggers a lysosomal mediated cell death pathway","volume":"287","author":"DiFranco","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.omtm.2025.101632_bib20","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1177\/0022034510363682","article-title":"Aggregatibacter actinomycetemcomitans leukotoxin: from threat to therapy","volume":"89","author":"Kachlany","year":"2010","journal-title":"J. Dent. Res."},{"key":"10.1016\/j.omtm.2025.101632_bib21","doi-asserted-by":"crossref","first-page":"489","DOI":"10.3390\/toxins11090489","article-title":"Aggregatibacter actinomycetemcomitans leukotoxin (LtxA; leukothera\u00ae): Mechanisms of action and therapeutic applications","volume":"11","author":"Vega","year":"2019","journal-title":"Toxins"},{"key":"10.1016\/j.omtm.2025.101632_bib22","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.1128\/iai.59.9.3267-3272.1991","article-title":"Lethal effects of Actinobacillus actinomycetemcomitans leukotoxin on human T lymphocytes","volume":"59","author":"Mangan","year":"1991","journal-title":"Infect. Immun."},{"key":"10.1016\/j.omtm.2025.101632_bib23","doi-asserted-by":"crossref","first-page":"5793","DOI":"10.1091\/mbc.e05-05-0413","article-title":"Dynamic partitioning into lipid rafts controls the endo-exocytic cycle of the alphaL\/beta2 integrin, LFA-1, during leukocyte chemotaxis","volume":"16","author":"Fabbri","year":"2005","journal-title":"MBoC."},{"key":"10.1016\/j.omtm.2025.101632_bib24","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.2174\/138161210791920450","article-title":"LFA-1 on leukemic cells as a target for therapy or drug delivery","volume":"16","author":"Phongpradist","year":"2010","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.omtm.2025.101632_bib25","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1182\/blood-2009-12-261487","article-title":"Elucidation of the integrin LFA-1\u2013mediated signaling pathway of actin polarization in natural killer cells","volume":"116","author":"Mace","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.omtm.2025.101632_bib26","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/ni1143","article-title":"Dynamic molecular interactions linking the T cell antigen receptor to the actin cytoskeleton","volume":"6","author":"Barda-Saad","year":"2005","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.omtm.2025.101632_bib27","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.1128\/MCB.00161-12","article-title":"Ubiquitylation-Dependent Negative Regulation of WASp Is Essential for Actin Cytoskeleton Dynamics","volume":"32","author":"Reicher","year":"2012","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.omtm.2025.101632_bib28","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1126\/science.1149859","article-title":"Systemic leukocyte-directed siRNA delivery revealing cyclin D1 as an anti-inflammatory target","volume":"319","author":"Peer","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.omtm.2025.101632_bib29","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1038\/s41598-022-06841-0","article-title":"Survival Genie, a web platform for survival analysis across pediatric and adult cancers","volume":"12","author":"Dwivedi","year":"2022","journal-title":"Sci. Rep."}],"container-title":["Molecular Therapy Methods & Clinical Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S232905012500227X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S232905012500227X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T20:29:46Z","timestamp":1776198586000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S232905012500227X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S232905012500227X"],"URL":"https:\/\/doi.org\/10.1016\/j.omtm.2025.101632","relation":{},"ISSN":["2329-0501"],"issn-type":[{"value":"2329-0501","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Leveraging the active conformation of LFA-1 as a potential target for hematological malignancies","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Methods & Clinical Development","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtm.2025.101632","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"101632"}}